Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
It's a great honor to have completed the present study and a pleasure to see it published.
In this study, we aimed to investigate the metabolomic, lipid, and lipoprotein early changes induced by bariatric surgery and antiobesity/antidiabetic drugs (i.e., GLP-1 RA) in patients with obesity and/or T2D; to explore the potential shared or distinct changes observed in the metabolome, the impact of weight loss as a potential confounder and whether the different types of bariatric surgery, (i.e., vertical sleeve gastrectomy and Roux-en-Y gastric bypass), may cause different effects on the metabolome.
Highlights
Bariatric surgery had a more pronounced effect on weight loss, metabolomic and lipidomic changes compared to liraglutide treatment at four and twelve weeks postoperatively.
Early metabolomic and lipidomic differences between bariatric surgery and liraglutide are attributed mainly to weight loss.
Acetoacetate, β-hydroxybutyrate, and citrate changes may reflect reduced calorie intake and diet-driven metabolomic and lipidomic alterations postoperatively.
Roux-en-Y gastric bypass and sleeve gastrectomy exhibit similar effects on metabolomic, lipid, and lipoprotein parameters.
This study promotes future research: on identifying surrogate markers to predict the effectiveness and cardiometabolic outcomes of these interventions; whether the beneficial cardiometabolic effects are weight-loss dependent or independent; providing an insight into the molecular implications of the different therapeutic approaches (i.e., pharmacological vs. surgical) allowing a more personalized approach and improving the health outcomes and healthcare management in patients with obesity and/or type 2 diabetes.
Read the full article here.